Anthracyclines: Selected New Developments Pp-113-130
[Abstract] [Purchase Issue/Articles]
Chemistry of Potent Anti-Cancer Compounds, Amphidinolides Pp-131-149
[Abstract] [Purchase Issue/Articles]
Targeting p53 in Cancer
Pp-151-161
[Abstract] [Purchase Issue/Articles]
Modulation of P-Glycoprotein
(PGP) Mediated Multidrug Resistance (MDR) Using Chemosensitizers: Recent
Advances in the Design of Selective MDR Modulators Pp-163-174
Rajesh Krishna and Lawrence D. Mayer
[Abstract] [Purchase Issue/Articles]
Porphyrin-based Sensitizers in the Detection and Treatment of Cancer: Recent Progress Pp-175-194
[Abstract] [Purchase Issue/Articles]
Synthesis, Proton-Affinity and Anti-Cancer Properties of the Prodigiosin-Group Natural Products Pp-195-218
[Abstract] [Purchase Issue/Articles]
[Back to top] [Purchase Issue/Articles]
Anthracyclines: Selected New Developments
Anthracycline antibiotics play an important role in cancer chemotherapy. The need for an improvement of their therapeutic index has stimulated an ongoing search for anthracycline analogues with improved properties. Analogue development was originally limited by a lack of information on the cellular drug target, nevertheless almost 20 years ago the mechanism of action of doxorubicin and daunorubicin was revealed and DNA topoisomerase II was recognised to be their main cellular target.
Several anthracyclines interfere with topoisomerase II functions by stabilizing a reaction intermediate in which DNA strands are cut and covalently linked to tyrosine residues of the enzyme. Investigations on the sequence specificity of doxorubicin in vitro and in nuclear chromatin of living cell have led to a molecular model of drug receptor on the topoisomerase II-DNA complex. Anthracyclines are likely placed at the interface between the DNA cleavage site and the active site of the enzyme, forming a DNA-drug-enzyme ternary complex. Moreover, a quite detailed structure-function relationship has been established for anthracyclines. First, drug intercalation is necessary but not sufficient for topoisomerase II poisoning; second, the removal of the 4-methoxy and 3’-amino substituents greatly increases the drug activity and third, the 3’ substituent of the sugar moiety markedly influences the sequence selectivity of anthracycline-stimulated DNA cleavage. These relationships have been exploited during the last decade by several groups, including ours, in the search for new anthracycline drugs with lower side effects and higher activity against resistant cancer cells.
This review will focus on areas of the anthracycline field including synthesis of new analogues, new strategies of synthesis and recent developments in the area of drug delivery.
[Back to top] [Purchase Issue/Articles]
Chemistry of Potent Anti-Cancer Compounds, Amphidinolides
Amphidinolides A-V represent a family of cytotoxic marine natural products with diverse structural features and pronounced biological activities. Kobayashi and his research group have been reporting over the years the discoveries of these remarkable molecules, one after another, since 1986 when the first report of the series appeared. Thanks to their perseverance and painstaking research, the family is still expanding. The unique structural features and biological activity profiles of these macrolides have obviously attracted the attention of organic chemists worldwide. The total syntheses of three members of the family, amphidinolides J, K and P, have already been achieved. This review tries to chronicle the fascinating chemistries of amphidinolides, studies on the syntheses of some of these molecules and their biological activity profiles.
[Back to top] [Purchase Issue/Articles]
Targeting p53 in Cancer
The loss of p53 function is a very important event in
cancer. The absence of a functional p53 in tumours favours cancer development,
and it has been suggested that it also influences the efficacy of both
chemotherapy and radiotherapy. The p53 pathway is therefore the subject of
intense research, both in academia and in industry, to identify new compounds
targeting tumours with an altered p53. Different strategies are currently under
investigation. They can be divided into two groups: biological and chemical
strategies. The biological strategies utilise the immune system to eliminate
the tumours overexpressing p53 mutants. Alternatively they use vectors
delivering a functional p53 gene in tumours or engineered viruses, which
selectively target p53-defective cells. The chemical strategies are based on
the design of compounds that stabilise or activate the p53 mutant proteins,
inhibit the interaction between p53 and hdm2, or act on the p53-binding
chaperone proteins. In this review, the current progress in these different
approaches will be analysed.
[Back to top] [Purchase Issue/Articles]
Modulation of P-Glycoprotein
(PGP) Mediated Multidrug Resistance (MDR) Using Chemosensitizers: Recent Advances
in the Design of Selective MDR Modulators
Over the past two decades, a number of chemical entities
have been investigated in the continuing quest to reverse P-glycoprotein (PGP)
mediated multidrug resistance (MDR) in cancer. The complexity of interactions
between these agents and the proteins responsible for MDR in conjunction with
the challenges associated with developing SAR/QSAR relationships for MDR
modulators has hampered our ability to develop agents that modulate MDR with
enhanced specificity of target, increased efficacy, and minimized toxicity when
coadministered with anticancer drugs. With an increased understanding of the
molecular interaction, target-mediated SAR and combinatorial chemistry
approaches, newer more selective inhibitors have been recently reported. These
agents have shown remarkable promise in preclinical trials; although their
ultimate clinical therapeutic utility remains to be established. The emphasis
of this review is placed on the current understanding of modulator-drug
transport protein interactions and to review the advances in the
structure-based design, synthetic efforts and the cellular pharmacology of MDR
modulating activity of a number of known PGP inhibitors.
[Back to top] [Purchase Issue/Articles]
Porphyrin-based Sensitizers in the Detection and Treatment of Cancer: Recent Progress
It has been known for some time that porphyrins and related compounds have the ability to selectively accumulate in tumor tissues, and to persist there for long periods of time. This property, along with the well-described photophysical and photosensitizing properties of porphyrin-type molecules, has led to their potential use as adjuvants and sensitizers in a variety of medical applications, such as in photodynamic therapy (PDT), boron neutron capture therapy (BNCT), radiation therapy (RT) and in magnetic resonance imaging (MRI). Both PDT and BNCT are binary cancer therapies that involve activation of tissue-localized sensitizers with either light (in PDT) or low-energy neutrons (in BNCT). In both of these therapeutic methodologies, local tumor control with minimal side effects relative to other forms of cancer treatment (surgery, radiotherapy, chemotherapy) can be achieved. Porphyrins constitute a major class of pharmacological agents currently under investigation. Photofrin, a porphyrin derivative, has been approved in the USA as a PDT drug by the U.S. Food and Drug Administration (FDA), and also in Japan, Canada and in eleven European countries. Recently, the FDA approved VisudyneTM, another porphyrin derivative for the PDT treatment of the ‘wet-form’ of age-related macular degeneration. In addition to cancer treatment porphyrins are also under investigation for application in the treatment of a variety of other diseases.
[Back to top] [Purchase Issue/Articles]
Synthesis, Proton-Affinity and Anti-Cancer Properties of the Prodigiosin-Group Natural Products
The prodigiosin-group natural products are a family of
tripyrrole red-pigments that are produced by microorganisms such as
Streptomyces and Serratia and contain a common 4-methoxy-2,2’-bipyrrole ring
system. They were first isolated in 1929 and studied as antibiotic and
cytotoxic agents in the 1960s, but were not developed clinically due to their
high systemic toxicity. However, during the past decade some prodigiosins have
shown potentially useful immunosuppressive activity when administered at doses
that are not toxic. They have also been found to exhibit selective cytotoxicity
against melanoma and liver cancer cells. These results have fueled various
studies on the biological mechanisms of the prodigiosins and it has now been
established that they inhibit phosphorylation and activation of JAK-3, a
cytoplasmic tyrosine kinase associated with the cell surface receptor component
called common g-chain. They also
uncouple lysosomal vacuolar-type ATPases through promotion of H+/Cl-
symport and facilitate oxidative double-strand DNA cleavage in the presence of
copper. A simple and elegant synthesis of the prodigiosins has also been
developed, which has allowed a number of the natural prodigiosins and synthetic
analogues to be prepared. These studies have served to renew interest in the
prodigiosin-group natural products. In this review the recent advances on the
synthesis, proton-affinity and biological activities of the prodigiosins are discussed.
With regard to their anti-cancer properties, particular attention is given to
their ability to facilitate oxidative DNA damage, which provides a rationale
for the cytotoxic properties of the prodigiosin-group natural products.